Complication of immune effector cellular therapy, subs

This code signifies a complication arising from immune effector cellular therapy, such as CAR T-cell therapy, during a follow-up visit. These complications can range from cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) to infections, cytopenias, or graft-versus-host disease (GVHD) specifically related to the cellular therapy.

Apply this code when a patient presents for ongoing management or evaluation of a previously diagnosed complication directly attributable to immune effector cellular therapy. This is appropriate for encounters after the initial treatment of the complication, where the patient is still experiencing or being monitored for its effects.

• Always sequence this code after the specific complication being treated (e.g., R50.81 for cytokine release syndrome).
• Ensure documentation clearly links the complication to the immune effector cellular therapy and indicates a subsequent encounter.
• Do not use for complications of other types of immunotherapy or for initial treatment of the complication.